Corpus Intelligence IC Memo — STONY BROOK UNIVERSITY HOSPITAL 2026-04-26 09:07 UTC
IC Memo — STONY BROOK UNIVERSITY HOSPITAL
Investment Committee Memorandum | NY | 725 beds | Grade C | EBITDA uplift $139.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

STONY BROOK UNIVERSITY HOSPITAL

CCN 330393 | SUFFOLK, NY | 725 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

STONY BROOK UNIVERSITY HOSPITAL is a 725-bed large academic medical center in SUFFOLK, NY with $1.90B in net patient revenue and a -4.9% operating margin. The hospital serves a payer mix of 35.4% Medicare, 5.0% Medicaid, and 59.6% commercial.

Thesis: Undervalued. Our ML models identify $139.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -4.9% to 2.4% (+736bps).

Net Revenue HCRIS$1.90B
Current EBITDA COMPUTED$-93.6M
Operating Margin COMPUTED-4.9%
Occupancy HCRIS89.9%
Revenue / Bed COMPUTED$2.6M
Net-to-Gross HCRIS28.1%
Distress Probability ML39.4%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
34
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -4.9% places it above the state median. Among 34 size-comparable peers (362-1450 beds), the median margin is -20.5%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (362-1450), prioritizing same-state peers. 34 hospitals in the comp set.

HospitalStateBedsRevenueMargin
STONY BROOK UNIVERSITY HOSPITA (Target)NY725$1.90B-4.9%
MEMORIAL HOSPITAL FOR CANCER ANY514$4.34B-32.5%
STRONG MEMORIAL HOSPITALNY749$3.31B5.2%
MOUNT SINAI HOSPITALNY1085$3.20B-12.1%
MONTEFIORE MEDICAL CENTERNY1410$3.01B-50.0%
LONG ISLAND JEWISH MEDICAL CENNY1161$2.97B-27.0%
NORTH SHORE UNIVERSITY HOSPITANY782$2.27B-50.0%
WESTCHESTER MEDICAL CENTERNY696$1.63B2.6%
KALEIDA HEALTHNY954$1.38B-8.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $139.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$39.9M+210bp18mo
Cost to Collect4.5%2.5%$38.0M+200bp12mo
Denial Rate Reduction12.0%6.5%$37.6M+198bp12mo
A/R Days Reduction5200.0%3800.0%$23.1M+122bp9mo
Clean Claim Rate88.0%96.0%$1.2M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$39.9M
Cost to Collect
$38.0M
Denial Rate Reduction
$37.6M
A/R Days Reduction
$23.1M
Clean Claim Rate
$1.2M
Total EBITDA Uplift$139.7M
Current EBITDA$-93.6M
+ RCM Uplift+$139.7M
Pro Forma EBITDA$46.0M
Current Margin-4.9%
Pro Forma Margin2.4%
WC Released (1x)$72.8M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-144.1M$779.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-144.1M$810.4M0.00x-100.0%
Bull Case9.0x11.0x$-129.7M$1.22B0.00x-100.0%
Bull (12x exit)9.0x12.0x$-129.7M$1.30B0.00x-100.0%
Bear Case11.0x10.0x$-158.5M$127.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-158.5M$88.8M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 34 hospitals with 362-1450 beds
  • Same-state prioritization (n=35)
  • Comp margins: P25=-32.5% / P50=-20.5% / P75=-9.0%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.